ClinicalTrials.Veeva

Menu

Non-Invasive Method for Evaluation of Cardiac Resynchronization Therapy (NIME-CRT)

University of Oslo (UIO) logo

University of Oslo (UIO)

Status

Enrolling

Conditions

Cardiovascular Diseases
Heart Failure
Heart Diseases
Cardiomyopathies
Pacemaker DDD

Treatments

Device: Cardiac Resynchronization Therapy (CRT)

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Left bundle branch block (LBBB) exists in about 25% of patients with congestive heart failure and is associated with worsened prognosis. Cardiac resynchronization therapy (CRT) has been one of the most important advancements in the past two decades for patients with LBBB heart failure. However, 30-40% of patients receiving a CRT do not benefit from it. In this study, the investigators will test a noninvasive device to evaluate acute effect of CRT during implantation and at follow-up CRT controls. In addition, echocardiography will be performed during CRT turned ON and OFF to visualize the changes in intraventricular flow and functional parameters of the heart.

Enrollment

80 estimated patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients referred for CRT implantation or postoperative control at Oslo University Hospital based on the European Society of Cardiology (ESC) guidelines (2021), and criteria below:

    1. Sinus rhythm.
    2. New York Heart Association class II / III heart failure on diagnosis and on optimal medical therapy.
    3. Left bundle branch block.
    4. QRS duration ≥ 130 ms.
    5. Left ventricular ejection fraction ≤ 40%.
    6. Patients must have echocardiography examination before implantation
    7. Informed consent obtained from the patient.

Exclusion criteria

  1. Age < 18 years and > 80 years;
  2. Ongoing atrial fibrillation;
  3. Complete atrioventricular block

Trial design

80 participants in 2 patient groups

Group 1 - Implantation
Description:
Patients admitted for CRT implantation according to current ESC/AHA guidelines
Treatment:
Device: Cardiac Resynchronization Therapy (CRT)
Group 2 - 6 months control
Description:
Patients admitted for 6 months routine checkups of their CRT devices
Treatment:
Device: Cardiac Resynchronization Therapy (CRT)

Trial documents
2

Trial contacts and locations

1

Loading...

Central trial contact

Marit Witsø, MD; Espen W. Remme, Dr.ing

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems